Biochanin A(Biochanin A) - 药物靶点：KDM1A x PDGFB_在研适应症：Legg-Calve-Perthes病，溃疡性结肠炎，肿瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

KDM1A x PDGFB

作用方式

抑制剂、刺激剂

作用机制

KDM1A抑制剂(赖氨酸特异性组蛋白脱甲基酶-1抑制剂)、PDGFB刺激剂(血小板衍生生长因子B亚基刺激剂)、表观遗传学药物

治疗领域

肿瘤免疫系统疾病消化系统疾病+ [2]

在研适应症

Legg-Calve-Perthes病溃疡性结肠炎肿瘤

非在研适应症-

原研机构

在研机构

非在研机构-

权益机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

结构/序列

分子式C16H12O5

InChIKeyWUADCCWRTIWANL-UHFFFAOYSA-N

CAS号491-80-5

关联

100 项与 Biochanin A 相关的临床结果

登录后查看更多信息

100 项与 Biochanin A 相关的转化医学

登录后查看更多信息

100 项与 Biochanin A 相关的专利（医药）

登录后查看更多信息

2,722

项与 Biochanin A 相关的文献（医药）

2025-12-01·CURRENT MICROBIOLOGY

Biochanin A Suppresses Growth and Biofilm Formation of Fluconazole-Resistant Candida auris

Article

作者: Jin, Hye-Won ; Eom, Yong-Bin

Invasive fungal infections, especially from Candida auris (C. auris), are a serious threat to immunocompromised patients because of multidrug resistance. Therefore, research into novel antifungal agents or adjuvants for pre-existing treatments is necessary. This study examined the therapeutic potential of biochanin A as an antifungal and anti-biofilm agent against fluconazole-resistant C. auris (FRCA). Its efficacy was determined through minimum inhibitory concentration (MIC), minimum biofilm inhibitory concentration (MBIC), and minimum biofilm eradication concentration (MBEC) assays. The fungal metabolic activity in biofilms was measured using the XTT reduction assay and the results were visualized by confocal laser scanning microscopy (CLSM). We also evaluated the effect of biochanin A on C. auris adhesion and the expression of resistance and virulence-associated genes. Biochanin A inhibited the growth of several C. auris strains, with MIC₉₀ values ranging from 16 to 64 µg/mL, as well as a dose-dependent reduction in MBIC and MBEC. The XTT assay and CLSM confirmed a significant inhibition of metabolic activity and viability. In addition, biochanin A reduced C. auris adherence to epithelial cells and downregulated the expression of the azole resistance gene ERG11 and the extracellular matrix gene KRE6. The results suggest that biochanin A is an effective alternative for managing fluconazole-resistant C. auris infections.

2025-11-01·PHYTOMEDICINE

Biochanin A alleviates endothelial cell senescence via epigenetic regulation of the HDAC1/H3K4me3/NFKB1 axis

Article

作者: Meng, Kun ; Mao, Aiqiu ; Wang, Xiaoying ; Zhang, Hui ; Lv, Jun ; Zhang, Tangya ; Cao, Zheng ; Li, Bo ; Ding, Yan ; Tu, Qiang

BACKGROUND:

Aging is a multifaceted physiological and pathological process, with endothelial cell senescence being a pivotal contributor to vascular aging. Biochanin A (BCA), a naturally occurring flavonoid, possesses known anti-inflammatory and antioxidant properties; however, its specific role and mechanism in combating endothelial senescence are not well defined.

PURPOSE:

This study aimed to investigate the potential anti-senescent effects of BCA on endothelial cells and aged vasculature, and to elucidate the underlying molecular mechanisms.

STUDY DESIGN:

The study employed a combination of in vitro cellular models and in vivo animal models to assess the effects of BCA on senescence. Mechanistic investigations were conducted to identify key molecular targets and pathways.

METHODS:

In vitro, an Angiotensin II (Ang II)-induced senescence model in human umbilical vein endothelial cells (HUVECs) was used. In vivo, naturally aged mice were treated with BCA. Senescence markers and SASP factors (e.g., IL-6, IL-8) were evaluated. RNA sequencing was performed to identify potential targets. Histone modification changes were analyzed through genomic binding site analysis, CUT&Tag assays, and chromatin immunoprecipitation quantitative PCR (ChIP-qPCR). Knockdown of histone deacetylase 1 (HDAC1) was achieved using siRNA to verify its necessity.

RESULTS:

BCA treatment effectively attenuated senescence markers and reduced senescence-associated secretory phenotype (SASP) levels in both Ang II-induced HUVECs and naturally aged mice. RNA sequencing identified HDAC1 as a key target. Mechanistically, BCA upregulated HDAC1, which subsequently suppressed the epigenetic aging marker H3K4me3. CUT&Tag and ChIP-qPCR analyses confirmed that this reduction in H3K4me3 occurred specifically at the promoter region of NFKB1 (p50), leading to its transcriptional downregulation. This inhibition of NFKB1 suppressed NF-κB signaling and the production of SASP factors. Crucially, HDAC1 knockdown completely abolished the anti-senescence benefits of BCA.

CONCLUSION:

Our findings demonstrate that Biochanin A alleviates endothelial and vascular senescence by targeting the HDAC1/H3K4me3/NFKB1 axis. This epigenetic mechanism inhibits NF-κB-mediated SASP production, positioning BCA as a promising natural epigenetic modulator to restore vascular homeostasis and mitigate age-related vascular dysfunction.

2025-10-29·JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Biorefining of Red Clover ( Trifolium pratense ) Yields a Phytoestrogen-Rich Byproduct with Potent Antiparasitic Activity

Article

作者: Megens, Naud ; Christiansen, Aslak H. C. ; Thamsborg, Stig M. ; Lübeck, Mette ; Williams, Andrew R. ; Bonde, Charlotte Smith

Biorefining of grasses and legume forages is carried out commercially to recover feed proteins for monogastric animals. The biorefining produces a fiber-rich pulp byproduct with additional valorization potential. Here, we explored whether pulp products from several biorefined plants could exhibit bioactivity against animal parasites. Among the tested plants, extracts derived from red clover possessed exceptionally high bioactivity against Ascaris suum larvae. GC-MS analysis revealed the antiparasitic compounds to be phytoestrogens, especially biochanin A and to a lesser extent formononetin. Higher concentrations of biochanin A and formononetin were found in biorefined pulp compared with unfractionated plants. These results underscore the dual benefit of biorefining: producing sustainable protein feed and valorizing residues for antiparasitic applications. These findings may offer a potential alternative to synthetic anthelmintics in addressing drug resistance challenges in livestock parasite management. Moreover, they pave the way for cost-effective, ecofriendly feed supplements, promoting circular economy principles in agriculture.

100 项与 Biochanin A 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
Legg-Calve-Perthes病	临床前	中国	广西医科大学第一附属医院	2025-07-02
溃疡性结肠炎	临床前	中国	武汉大学人民医院	2025-03-26
肿瘤	临床前	中国	郑州大学	2020-04-01